Sign In
Buy NVS
$148.93
+1.85 (+1.26%)
At Close: Jun 22, 2026
Jones Financial Companies Lllp Buys 12,457 Shares of Novartis AG $NVS
04:36am, Wednesday, 04'th Feb 2026
Jones Financial Companies Lllp raised its position in shares of Novartis AG (NYSE: NVS) by 7.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commi
Novartis Sales Rise Despite Generic Drug Competition in U.S.
01:35am, Wednesday, 04'th Feb 2026
The pharma major said it had strong results in 2025, but guided toward a decline in core operating profit this year.
Novartis expects low single-digit decline in 2026 operating profit
01:12am, Wednesday, 04'th Feb 2026
Swiss drugmaker Novartis forecast a decline in 2026 operating profit in the low single-digit percentage range on Wednesday, held back by competition from cheaper copies of established products such as
Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025
01:00am, Wednesday, 04'th Feb 2026
Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +8% (cc 1 , +8% USD) with core operating income 1 up +14% (cc, +12% USD) Sales growth driven by continued strong performance from pr
Federated Hermes Inc. Cuts Stake in Novartis AG $NVS
03:24am, Tuesday, 03'rd Feb 2026
Federated Hermes Inc. lowered its stake in shares of Novartis AG (NYSE: NVS) by 48.4% in the undefined quarter, according to the company in its most recent disclosure with the SEC. The firm owned 51,4
Woodmont Investment Counsel LLC Has $3.62 Million Holdings in Novartis AG $NVS
04:30am, Monday, 02'nd Feb 2026
Woodmont Investment Counsel LLC lessened its position in shares of Novartis AG (NYSE: NVS) by 18.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commi
Frank Rimerman Advisors LLC Acquires 3,830 Shares of Novartis AG $NVS
04:49am, Sunday, 01'st Feb 2026
Frank Rimerman Advisors LLC increased its holdings in shares of Novartis AG (NYSE: NVS) by 68.1% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 9,451 shares
Why Novartis (NVS) is a Top Value Stock for the Long-Term
10:40am, Friday, 30'th Jan 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exploring Analyst Estimates for Novartis (NVS) Q4 Earnings, Beyond Revenue and EPS
10:15am, Friday, 30'th Jan 2026
Evaluate the expected performance of Novartis (NVS) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics
Belpointe Asset Management LLC Buys Shares of 6,238 Novartis AG $NVS
04:36am, Friday, 30'th Jan 2026
Belpointe Asset Management LLC purchased a new position in shares of Novartis AG (NYSE: NVS) during the undefined quarter, according to the company in its most recent 13F filing with the SEC. The inst
Some of Pharma's Biggest Brands Face a New Reality
09:48am, Wednesday, 28'th Jan 2026
Big pharma just got another nudge from Washington that Medicare pricing pressure is only moving in one direction. A new batch of well-known drugs from Pfizer (P
Compass Wealth Management LLC Sells 11,454 Shares of Novartis AG $NVS
06:24am, Wednesday, 28'th Jan 2026
Compass Wealth Management LLC trimmed its position in shares of Novartis AG (NYSE: NVS) by 86.0% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securiti
Cogent's New Stomach Cancer Treatment Cuts Progression Risk In Half, Gets Breakthrough Therapy Tag
10:06am, Monday, 26'th Jan 2026
The FDA granted breakthrough status to Cogent's GIST drug combo after a trial showed it cut disease progression or death risk by 50% compared with current treatment.
Novartis CEO on impact of 'most favored nation' drug pricing
02:45pm, Thursday, 22'nd Jan 2026
Novartis CEO Vas Narasimham, speaking with CNBC about lowering drug prices, said the focus should be on reducing patient out-of-pocket drug costs, not list or net prices, though believes progress is m
Novartis CEO Vas Narasimhan: ‘We really should be talking about out-of-pocket costs' in the U.S.
12:03pm, Thursday, 22'nd Jan 2026
Vas Narasimhan, CEO of Novartis, joins 'Money Movers' to discuss U.S. drug pricing, healthcare, and more.
